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Abstract
Objective To systematically review published and unpublished efficacy
studies of agomelatine in people with depression.
Design Systematic review and meta-analysis.
Data sources Literature search (Pubmed, Embase, Medline), Cochrane
Central Register of Controlled Trials, EuropeanMedicines Agency (EMA)
regulatory file for agomelatine, manufacturers of agomelatine (Servier).
Eligibility criteria Double blind randomised placebo and comparator
controlled trials of agomelatine in depression with standard depression
rating scales.
Data synthesis Studies were pooled by using a random effects model
with DerSimonian and Laird weights for comparisons with placebo and
comparator antidepressant. The primary efficacy measure (change in
rating scale score) was summarised with standardised mean difference
(SMD; a measure of effect size) and secondary outcome measures with
relative risks. All results were presented with 95% confidence intervals.
Statistical heterogeneity was explored by visual inspection of funnel
plots and by the I2 statistic. Moderators of effect were explored by
meta-regression.
ResultsWe identified 20 trials with 7460 participants meeting inclusion
criteria (11 in the published literature, four from the European Medicines
Agency file, and five from the manufacturer). Almost all studies used the
17 item Hamilton depression rating scale (score 0-50). Agomelatine was
significantly more effective than placebo with an effect size (SMD) of
0.24 (95% confidence interval 0.12 to 0.35) and relative risk of response
1.25 (1.11 to 1.4). Compared with other antidepressants, agomelatine
showed equal efficacy (SMD 0.00, −0.09 to 0.10). Significant
heterogeneity was uncovered in most analyses, though risk of bias was
low. Published studies were more likely than unpublished studies to
have results that suggested advantages for agomelatine.
Conclusions Agomelatine is an effective antidepressant with similar
efficacy to standard antidepressants. Published trials generally had more
favourable results than unpublished studies.
Introduction
Agomelatine is a novel antidepressant approved in February
2009 for use in the European Union.1 It is thought to act through
a combination of antagonist activity at 5HT2C receptors and
agonist activity at melatonergic MT1/MT2 receptors.
2 As such,
its pharmacology is unique among licensed antidepressant drugs,
possessing no ability to interfere with the neuronal reuptake of
serotonin, norepinephrine (noradrenaline), or dopamine. A
meta-analysis of published trials suggested robust efficacy in
major depression, with an estimated effect size of 0.26 compared
with placebo.3
In medicine there is considerable concern over selective
publication of trials with positive results—so called publication
bias. With antidepressants, this was first commented on after
the apparent suppression of negative data for antidepressants
used in children.4More recently, public access to details of trials
registered with regulatory authorities has allowed a fuller
assessment of the efficacy of newer antidepressants. For
example, an analysis of antidepressant trials registered with the
US Food and Drug Administration (FDA) found that 31% of
registered trials were not published, most of them having
negative findings.5 Of published studies, 95% had positive
results, but of all studies only 51% had positive results. Analysis
of both published and unpublished studies reduced the overall
estimated effect size from 0.41 (published studies) to 0.31 (all
studies). A similar, and again more complete, analysis of studies
of the antidepressant reboxetine strongly suggested that it was
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in fact ineffective in major depression, showing no superiority
over placebo when all studies were considered.6
We assessed the efficacy of agomelatine using both published
trials and unpublished studies obtained from regulatory
authorities and from the manufacturer.
Method
Eligibility criteria
Studies evaluating the efficacy of agomelatine in acute treatment
(6-12 weeks) of depression in adults were eligible for inclusion.
Included studies also had to be randomised, double blind, and
controlled (placebo and/or other antidepressant). Patients needed
to meet criteria for major depressive disorder as defined by each
study.We considered only those studies evaluating agomelatine
at the licensed recommended doses of 25 mg or 50 mg. Studies
recruiting patients for evaluation of other outcomes were
considered provided they met criteria for major depressive
disorder as defined above and had collected data for outcomes
in depression. Studies were excluded if the main outcome was
prevention of relapse or if outcomes for the treatment of
depression in the acute phase were not available.
Outcome measures
The main outcome was the change in mean scores on a
depression rating scale at the end of treatment. We considered
studies using established depression rating scales such as the
Hamilton rating scale for depression (HAM-D)7 or the
Montgomery-Åsberg depression rating scale (MADRS).8
Secondary outcome measures were response and remission of
depression as defined by the primary studies. Most defined
response as 50% reduction in baseline rating scale measurements
and remission as HAM-D ≤7 or MADRS ≤12.
The emphasis of our review was efficacy and so we based
selection criteria on factors related to efficacy outcomes. We
did not intend to systematically evaluate adverse outcomes, but
to set in context efficacy findings we also recorded outcomes
related to tolerability and harms. Specifically, when available,
we recorded early discontinuations from studies (both in total
and those specifically related to adverse effects).
Search strategy and study selection
We searched for studies meeting our inclusion criteria using the
following search terms: agomelatine, controlled trial, double
blind, and depression. There were no limits applied for language
and date of publication. We undertook a full electronic search
of the following databases from inception to 2013: Embase,
Medline, Cochrane Central Register of Controlled Trials, and
PubMed, with the last search performed in March 2013. We
also searched references lists of retrieved articles, conference
abstracts, and trials registries for additional studies. We applied
to the European Medicines Agency (EMA) for details of all
studies submitted in support of regulatory approval of
agomelatine. We also contacted the European manufacturer of
agomelatine, Servier, and requested details of published and
unpublished studies.
Studies were first identified for inclusion by examining the title
and abstract of each record.We then sought the full text version
of suitable articles before applying the inclusion criteria. Two
authors (OO andAS) applied the inclusion criteria independently
to identify studies for the meta-analysis. Any discrepancies were
resolved by consensus.
Data extraction
Using a standard spreadsheet, two authors (OO and SV)
extracted data independently and any discrepancies were
resolved by consensus. The following data were extracted:
• Participants’ characteristics: age, sex, diagnosis, and
measures of severity of depression (symptom rating scales)
• Treatment: type of comparator (active or placebo), dose,
and duration of treatment
• Outcome measures: mean baseline and final depression
rating scale scores and corresponding standard deviations
(SDs), analysis of covariance (ANCOVA) effect estimates
(when available) and corresponding standard errors, and
number of responders and remitters in each treatment group
• Information necessary to assess the risk of bias in included
studies.
All outcome data were extracted on an intention to treat principle
as defined in the primary studies.When information wasmissing
on essential variables we contacted authors for further
information.
Risk of bias
Two authors independently assessed the risk of bias in individual
studies, and any disagreements were resolved by discussion.
According to recommendations from the Cochrane
Collaboration9 we assessed the risk of bias associated with
sequence generation, allocation concealment, blinding of
participants and investigators, blinding of outcome assessment,
incomplete outcome data, selective outcome reporting, and other
bias. Each domain was rated as low, high, or unclear. Overall,
risk of bias for each study was judged on the first three items:
sequence generation, allocation concealment, and blinding.
Studies judged to have a high risk of bias on these domains were
excluded from the main analysis.
Data synthesis
The primary summary measure of treatment effect is the
standardised mean difference (SMD) using the method of
Hedges (Hedges g).10 The SMD, which is the difference in mean
final values between agomelatine and comparator standardised
by the standard deviation, was chosen in preference to raw scores
to enable results of different rating scales to be combined in the
same analysis. The preferred measure of effect is an estimate
produced by analysis of covariance (ANCOVA), which adjusts
for baseline imbalances. This outcome is not often reported in
trials of antidepressants, however, so we opted to use final values
in favour of change scores as the former is equivalent to using
ANCOVA estimates when there is no baseline imbalance.11
Moreover use of final values as the outcome measure saves the
effort of having to impute standard deviations, which are often
missing from results of outcomes with change scores.
For the secondary outcome measures, we computed risk ratios
for responders and remitters and pooled across studies.
All analyses were performed with a random effects
meta-analysis with DerSimonian and Laird weights. Separate
analyses were conducted each for comparison of placebo and/or
antidepressant with agomelatine. Studies that evaluated more
than one dose of agomelatine were combined to form one
composite measure as described by Borenstein and co-workers.10
All effect sizes were presented with corresponding 95%
confidence intervals and P values. Non-significance was
concluded if confidence intervals included 0 for continuous
outcomes or 1 if outcomes were ratio measurements.
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To test the robustness of methods used for our primary analyses
we planned the following sensitivity analyses:
• Summarising effects with a fixed effect model
• Summarising with available ANCOVA estimates
• Summarising with raw mean differences (HAM-D)
• Summarising with final raw final values (HAM-D)
• Restricting analyses to studies considered to have a low
risk of bias.
Heterogeneity in effect sizes was explored by visual inspection
of forest plots and quantified with the I2 statistic. For
comparisons that showed considerable amount of heterogeneity
(defined as I2 >50%) we further explored possible reasons for
variation. As determined a priori, possible moderators of
effect—such as treatment duration, dose of antidepressant, age,
number of previous episodes, and aspects of study quality such
as low risk of bias and allocation concealment—were considered
for entry into a meta-regression.
We explored bias in study availability (“publication bias”) by
visual inspection of funnel plots and by Egger’s test to test for
funnel asymmetry. Analyses were performed with Revman 512
and Stata 11.13
Results
Description of studies
We completed our literature search in March 2013, and we also
received a CD from the EMA giving full details of trials used
in the regulatory process. Also inMarch 2013 the manufacturer,
Servier, supplied internal reports of all completed trials
sponsored by them. We identified 193 records from these
sources (fig 1⇓). After applying eligibility criteria, we considered
24 studies for inclusion but, on further examination, we excluded
four of them.14-17
Overall, we included in the meta-analysis 20 trials (n=7460),18-37
making 12 pairwise comparisons with placebo and 13
comparisons with other antidepressants. The sources of these
included studies were as follows: 11 were indentified in our
literature search18 27-36; four more were found in the EMA
submission document19-22; and full details of five further studies
were provided by the manufacturer, Servier23-26 37 (one of which26
was published in full38 during manuscript preparation). Servier
also confirmed that there were no other completed studies known
to them other than those we had ourselves identified and those
about which they had notified us.
Most studies were multicentred and multinational, being
conducted in 32 different countries (appendix). All studies were
published in English; three studies were conducted in the United
States, one in Asia, and the remainder in Europe and other parts
of the world including South Africa and South America. Patients
were diagnosed with major depressive disorder with criteria
defined by the diagnostic and statistical manual of mental
disorders, DSM-IV. With the exception of two studies,22 36 all
studies used the HAM-D as their primary depression rating tool.
One study included a small number (<2%) of patients with
bipolar II depression.31
Several studies recruited depressed patients with the primary
intention of evaluating conditions separate from depression:
quality of sleep function (three studies)25 33 39 and sexual
functioning (one study).36 Participants were considered to be
moderately/severely ill at baseline with mean HAM-D score of
27.0 (SD 1.0) (using a cut off HAMD score of 23, as suggested
by National Institute for Clinical Excellence guidelines in
depression).40 Three studies specifically recruited adults aged
over 60,22 23 26 and one study included only patients with severe
depression (HAM-D ≥25).27 All studies had a preponderance
of female participants, with proportions ranging from 58.4% to
77%. Antidepressants compared with agomelatine included
escitalopram (n=2), fluoxetine (n=4), sertraline (n=1), paroxetine
(n=4), and venlafaxine (n=2). Studies lasted from six weeks to
12 weeks. One trial, which was designed as a dose finding study,
included low doses of agomelatine (1 mg and 5 mg),31 which
are not licensed doses in the UnitedKingdom.Another examined
10 mg a day alongside 25 mg and 50 mg.37 Likewise 10 mg a
day is not a licensed dose in the UK. These unlicensed doses
were not included in the final analysis.
All studies included patients from what was described as the
full analysis set, which is based on intention to treat principles.
The full analysis set consisted of patients receiving at least one
dose of drug and having at least one measurement after baseline.
All studies reported using the last observation carried forward
method for missing observations.
Risk of bias
Figure 2⇓ shows the risk of bias across all studies. Most studies
lacked sufficient information for full assessment. The
unpublished reports supplied to us in general had more detail
than published studies to allow a full assessment. Ten studies
were considered as having a low risk of bias with respect to
methods for sequence generation (fig 3⇓). Blinding of
participants and staff, when described, was of low risk or unclear
risk, with none regarded as having high risk. Allocation
concealment was considered adequate in most trials (13/20,
65%). We noted high risk of bias for two studies with regards
to selective outcome reporting. Across all studies, the risk of
bias was considered low or unclear based on evaluation of the
first four domains, with eight studies meeting the criteria for
low risk.
Quantitative analyses
As there were several unpublished studies, we decided (post
hoc) to stratify each analysis by publication status.
Agomelatine v placebo
Twelve studies reported outcomes for 3951 randomised patients,
which provided an intention to treat sample of 3855 patients for
the primary analysis. Heterogeneity in effect sizes was
substantial with I2=66% (fig 4⇓). There was a significant
difference favouring agomelatine (SMD 0.24, 95% confidence
interval 0.12 to 0.35).
For secondary analyses, patients were more likely to respond
to agomelatine than placebo (relative risk 1.25, 95% confidence
interval 1.11 to 1.41; fig 5⇓). Heterogeneity was high with
I2=63%. In 11 studies reporting remission, there was no
significant difference in remission rates between the agomelatine
and placebo group (1.22, 0.97 to 1.53; fig 6⇓). Again,
heterogeneity was high with I2=56%.
Agomelatine v antidepressants
Thirteen studies (n=4559 randomised patients) were included
in the primary analysis, providing an intention to treat sample
of 4467 patients. Heterogeneity between effect sizes was
substantial at I2=59%. There was no significant difference
between groups (SMD 0.00, 95% confidence interval −0.09 to
0.10; fig 7⇓). Responder analysis (10 studies) showed no
significant difference between groups (relative risk 1.01, 0.94
to 1.09) with moderate heterogeneity (I2=47%) (fig 8⇓). In eight
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:g1888 doi: 10.1136/bmj.g1888 (Published 19 March 2014) Page 3 of 19
RESEARCH
 o
n
 7 July 2020 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.g1888 on 19 March 2014. Downloaded from 
studies reporting remission there was no difference in remission
rates between the two groups (0.97, 0.79 to 1.20; I2=67%; fig
9⇓).
We directly assessed variability in outcome related to
comparator antidepressant by producing forest plots of the
primary outcome examining each comparator in turn (fig 10⇓).
Few clear differences in outcome were apparent: agomelatine
was significantly more effective than sertraline (SMD 0.23,
95% confidence interval 0.01 to 0.46), and there was a trend
for agomelatine to be less effective than paroxetine (–0.13,
−0.33 to 0.06).
Tolerability/harms
Data on overall discontinuation were available for 12
comparisons with placebo (2317 participants for agomelatine;
1634 for placebo) and 12 comparisons with comparator
antidepressants (2215 participants for agomelatine; 2067 for
comparator). Data on discontinuations because of adverse effects
were available for the same number of studies and subjects for
placebo comparisons but for 13 studies using active comparators
(2352 participants for agomelatine; 2207 for comparator).
All cause discontinuations
In placebo comparisons, all cause discontinuations were
410/2317 (18%) for agomelatine and 313/1634 (19%) for
placebo (fig 11⇓). In active comparator trials 377/2215 (17%)
discontinued agomelatine and 392/2067 (19%) comparator
antidepressants (fig 12⇓). Patients were no more likely to
discontinue agomelatine than placebo (relative risk 0.92, 95%
confidence interval 0.78 to 1.08; fig 11⇓) or comparator
antidepressant (0.90, 0.76 to 1.07; fig 12⇓).
Discontinuations because of adverse effects
In placebo comparisons, discontinuations because of adverse
effects were 97/2317 (4%) for agomelatine and 65/1634 (4%)
for placebo (fig 13⇓). In active comparator trials 108/2352 (5%)
discontinued agomelatine and 174/2207 (8%) discontinued
comparator antidepressants (fig 14⇓).
Participants randomised to agomelatine were no more likely to
discontinue because of adverse effects than those randomised
to placebo (relative risk 1.03, 95% confidence interval 0.75 to
1.41) (fig 13⇓). Those randomised to agomelatine were less
likely than those receiving comparator antidepressants to
discontinue treatment because of adverse effects (0.61, 0.48 to
0.78; fig 14⇓).
Sensitivity analysis
We did not undertake a sensitivity analysis of studies with low
risk of bias for placebo comparisons as this would have resulted
in a meta-analysis of only four studies, which would be
insufficient to drawmeaningful conclusions. For similar reasons
we did not pool ANCOVA estimates or studies with low risk
of bias for agomelatine versus antidepressants. The results of
other sensitivity analyses did not significantly alter the direction
or magnitude of the results in any of the comparisons (table 1⇓).
Meta-regression
Table 2⇓ shows the impact of effect moderators on the outcome.
We were not able to fully explore the moderators of effect as
planned because studies were either too few (age) or lacked
sufficient variation in the covariate of interest (antidepressant
dose and number of previous episodes) to produce meaningful
results. Instead, we explored the effect of low risk of bias,
allocation concealment, treatment duration, and duration of
current episode in univariate analyses. There was no evidence
of effect modification in the agomelatine versus placebo analyses
for any of the variables tested. We found a non-significant
association between allocation concealment and effect size, with
adequate concealment associated with larger effect sizes.
Allocation concealment explained 38% of the heterogeneity
seen between studies of agomelatine compared with another
antidepressant.
Publication/availability bias
Figures 15⇓ and 16⇓ show funnel plots of standardised mean
differences by publication status. As included studies were of
similar size (and thus precision), we could not tease out small
study effects (smaller studies showing larger effects) from the
funnel plots. Visual inspection of funnel plots and result of
Egger’s test showed no evidence of funnel plot asymmetry for
comparisons with placebo (P=0.793) (fig 15⇓) and
antidepressants (P=0.949) (fig 16⇓). The plots did, however,
show evidence of publication bias: unpublished studies were
more likely to show positive results.
Discussion
This meta-analysis of completed trials of agomelatine in
depression suggests an effect size for agomelatine compared
with placebo of 0.24 (95% confidence interval 0.12 to 0.35), a
relative risk of response of 1.25 (1.11 to 1.41), and relative risk
of remission of 1.22 (0.97 to 1.53). Overall, agomelatine showed
equal efficacy to other antidepressants on all measures, with
little likelihood of important differences in efficacy in either
direction.We can conclude that agomelatine is an antidepressant
with similar efficacy to standard drug treatments; an important
finding given its unique mode of action. Its failure to show
statistical superiority to placebo for remission could reflect the
fact that not all studies reported this outcome and so power to
discern differences was accordingly reduced. Our unplanned
analysis of acceptability showed that agomelatine was broadly
better tolerated than comparator antidepressants.
Comparison with other antidepressants
An estimated effect size of 0.24 is small in absolute terms (see
table 3⇓) and is somewhat lower than that calculated from
comprehensive reviews of trials of other antidepressants (effect
size estimated at 0.315). If we accept that agomelatine is as
effective as other antidepressants, as our analysis strongly
suggests, then these disparate estimates require explanation.
One probable contributor is the strengthening of placebo
response in depression trials over time: the effect of placebo
has increased substantially over the past decades,41meaning that
more recently examined drugs are likely to show a relatively
small effect size compared with placebo. It is also possible that
the effect size estimates derived for other antidepressants might
be based on incomplete datasets and might not include
unregistered or otherwise “hidden” studies with negative results,
leading to an overestimate of their effect size. It is also worthy
of note that the confidence intervals around our estimated effect
size (0.12 to 0.35) include the effect size estimated for other
antidepressants.
Publication bias
Visual inspection of our forest plots and funnel plots shows that
unpublished studies tend to have less favourable results for
agomelatine. With placebo as the comparator, the effect size
was 0.21 (95% confidence interval 0.01 to 0.40) for unpublished
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studies and 0.26 (0.16 to 0.36) for published studies. Results of
unpublished studies suggested no advantage for agomelatine
over placebo in respect to response and remission. In
comparisons with other antidepressants, published studies
favoured agomelatine (standardised mean difference 0.14, 95%
confidence interval 0.05 to 0.23) and unpublished studies tended
to favour the comparator (−0.10, −0.20 to 0.01). In unpublished
comparator studies, treatment response was statistically more
likely with the comparator antidepressant—the opposite finding
of the combined results of published studies. Overall, there is
a strong impression of publication of trials whose results
favoured agomelatine and the non-publication of less favourable
trials (although Servier’s willingness to provide us with all data
relating to trials of agomelatine should be noted).
Agomelatine is clearly an effective antidepressant, but its
efficacy is undoubtedly overestimated when only published
studies are considered—an observation confirmed by the results
of other smaller meta-analyses, which have largely included
only selected published data.3 42 43 Themost recent meta-analysis
including both published and unpublished studies estimated
agomelatine’s effect size compared with placebo to be 0.18.43
This analysis did not include recently completed unpublished
studies or studies with an active comparator. Table 4⇓
summarises the results of this study and previous meta-analyses.
Comparisonwith other specialties inmedicine
The effect size of agomelatine estimated here, and that of other
antidepressants, might suggest some doubt over their clinical
utility and lend support to those who call for a more restricted
use of antidepressants. Three observations should, however, be
taken into account. Firstly, the effect size for antidepressants
compared with placebo might be small, but the effect size of
placebo itself in major depression has been estimated to be
greater than 0.9.44 Indeed, placebo shows a clear “dose related”
effect in depression: the more patients are visited and examined,
the better their response.45 Secondly, where placebo effects are
less apparent, in, for example, the prevention of depressive
relapse, antidepressants show much higher effect sizes, usually
greater than 0.5.46 Thirdly, even the small effect sizes calculated
for antidepressants in acute treatment are not dissimilar to those
observed in medical conditions such as hypertension (effect size
for ACE inhibitors in prevention of cardiovascular events is
0.16) and acute stroke (effect size of thrombolysis on survival
is 0.11).46As with the use of other antidepressants, agomelatine
might be expected to result in the improvement of perhaps three
quarters of patients, although most these will be placebo
responders.
Limitations
As with many meta-analyses our study has several limitations.
We considered only short term efficacy studies of agomelatine,
some of which did not have changes in depression rating scores
as their primary outcome. The risk of bias assessment was
hindered by poor reporting, thereby making it difficult to judge
the quality of studies for some particular domains (such as
sequence generation). Another potential limitation is that we
aggregated data for 25 mg and 50 mg doses of agomelatine,
which could result in some heterogeneity in effect size
estimation. Agomelatine, however, has not shown a clear dose
response relation between 25 mg and 50 mg a day, with
outcomes for the two doses invariably being near identical and
no clear pattern for one dose more often being more effective
than another. Lastly, a particular concern was the high level of
heterogeneity observed for both placebo controlled and
comparator controlled studies and our inability to identify
variables likely to be significant contributors to this
heterogeneity. Interestingly, the one study that contributed most
to the heterogeneity of placebo controlled outcomes was a study
with particularly positive results for agomelatine, largely because
of a much smaller placebo response than in other studies and
not because of an unusually high absolute response to
agomelatine.37 Perhaps most importantly we can be reasonably
confident that we have captured all available data, taking into
account the information supplied to us by the European
Medicines Agency and by the manufacturer and the appearance
of the funnel plots.
Strengths
Clearly the major strength of this analysis is that we have
analysed what we believe to be all available suitable data from
completed studies of agomelatine (as shown in our funnel plots)
by a robust method that enabled minimisation of risk of bias.
Data capture is perhaps the most important aspect of
comprehensive meta-analysis, and the incalculable impact of
reporting or publication bias is well recognised.47 48
Our analysis, the largest conducted to date, shows a modest
effect for agomelatine compared with placebo (an effect both
overestimated 3 and underestimated 43 in previous analyses) and
its equivalence to comparator drugs (superior efficacy for
agomelatine being suggested in previous meta-analyses3 42).
This study is perhaps a unique example of where working with
regulatory authorities and drug manufacturers allows a full and
realistic appraisal of the efficacy of a marketed drug.
Agomelatine in clinical guidelines
The most recent NICE guideline on depression published in
2009 did not include agomelatine because the drug was “not
licensed at the time of data analysis.”40 Agomelatine is briefly
mentioned in NICE guidelines on depression in chronic physical
illness as one of a number of “third generation antidepressants.”49
Both guidelines recommend switching to “a better tolerated,
newer-generation antidepressant” when there is inadequate
response to a selective serotonin reuptake inhibitor (SSRI). This
somewhat vague description could be said to include
agomelatine, although mirtazapine, duloxetine, and perhaps
trazodone are also implied. There is strong evidence in this
analysis that agomelatine is indeed “better tolerated.”
The Maudsley Prescribing Guidelines in Psychiatry suggest
agomelatine as a possible choice of treatment after failure of
two previous antidepressants.50 Support for this “third line”
positioning is rather weak and based on a single naturalistic
study,51 and theoretical considerations related to mode of
action—that is, a different pharmacological action from
SSRIs—might produce a response. Agomelatine is also
recommended in these guidelines as an alternative to other
antidepressants when poor tolerability or contraindications
preclude the use of SSRIs, serotonin-norepinephrine reuptake
inhibitors (SNRIs), or mirtazapine.
Agomelatine—place in treatment
Agomelatine is a branded drug still protected by patent and
therefore considerably more expensive than any of the large
number of generic alternatives. Its use is further inhibited by
the formal requirement for liver function testing at baseline and
three, six, 12, and 24 weeks.52 This monitoring is mandated
because of a low but important incidence (1.3%) of raised liver
enzyme activity52 and the risk of non-fatal “toxic hepatitis”—six
cases were reported from analysis of a German database,53
although only three cases of apparent liver “toxicity” (two
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cholelithiasis, one jaundice) have been reported in the UK since
its introduction.54 In neither case do available data allow the
calculation of the likely incidence of serious hepatic reaction
to agomelatine. (Assessment of toxicity was not a specific
objective of our analysis, and indeed we found no useful data
relating to risk of hepatic reactions.)
Thus, despite agomelatine’s apparent equal efficacy to standard
antidepressants, its costs and monitoring requirements make it
unsuitable as a first line treatment. Agomelatine is a drug worthy
of consideration because of its better tolerability and use in
patients with adverse effects with standard antidepressants.
SSRIs are sometimes poorly tolerated because they cause
nausea, insomnia, and sexual dysfunction.55 Agomelatine has a
low incidence of nausea,52 improves sleep,56 and seems not to
affect sexual function.36 57 In addition, SSRIs are sometimes
contraindicated because of their effect on blood clotting and the
consequent risk of bleeding.58 59 Mirtazapine is often suggested
as an alternative,49 but its use is complicated by weight gain60
and somnolence.61 Agomelatine does not seem to affect the
blood clotting mechanism and has a low incidence of weight
gain.52 Lastly, the use of perhaps all standard antidepressants is
associated with discontinuation symptoms,62which do not seem
to occur with agomelatine.16On balance, therefore, agomelatine
is one of several sensible treatment options for those patients
who cannot take standard antidepressants.
Agomelatine in long term treatment
In this analysis we focused on short term efficacy studies, but
of course depression is often a chronic recurring condition.
Pooled analysis of four published 24 week studies suggested
that agomelatine was at least as effective as treatment with an
SSRI.63Agomelatine also seems to prevent relapse of generalised
anxiety disorder over a six month period.64 There is one
published 24 week relapse prevention study of agomelatine14 in
depression, which showed a significant advantage for
agomelatine over placebo. A meta-analysis including this and
two further unpublished relapse prevention studies, however,
suggested no advantage for agomelatine over placebo.43 The
long term benefit of agomelatine thus remains unproved.
Conclusion
In this comprehensive meta-analysis of both published and
unpublished studies we have shown that agomelatine is
moderately more effective than placebo and has similar efficacy
to standard antidepressants. It is clear, however, that many
studies of this drug with negative or equivocal results have not
been published. Any meta-analysis of a less than exhaustive
selection of completed studies is therefore likely to give
erroneous results. Nonetheless, agomelatine’s demonstrable
acute efficacy is intriguing given its unique pharmacological
mode of action and good tolerability, and our findings certainly
support further research into compounds possessing
melatonergic activity. That agomelatine is no less effective than
comparator antidepressants is also noteworthy given its
relatively small risk of sexual adverse effects, insomnia, and
discontinuation reactions (all commonly seen with serotonergic
antidepressants). As such it serves as an appropriate alternative
to these longer established antidepressants, although its relative
cost, the small risk of hepatic toxicity, and need for liver
function monitoring should be noted.65
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Tables
Table 1| Sensitivity analyses of studies on antidepressant efficacy of agomelatine
I2 (%)Effect size (95% CI)No of studiesMeta-analysis
Agomelatine v placebo
660.23 (0.17 to 0.30)12Fixed effect model using final scores
660.23 (0.12 to 0.34)12Random effects model using changes scores
681.9 (0.94 to 2.87)*10Random effects model using ANCOVA estimates (HAM-D scores only)
601.97 (1.12 to 2.82)†11Random effects model using raw HAM-D final scores
Agomelatine v other antidepressant
591.00 (−0.06 to 0.06)13Fixed effect model using final scores
56−0.01 (−0.10 to 0.10)13Random effects model using changes scores
630.06 (−0.40 to 0.53)†12Random effects model using raw HAM-D final scores
*Raw mean differences on HAM-D scale adjusted for baseline scores.
†Raw mean differences on HAM-D scale.
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Table 2| Meta-regression of effect modifiers
Proportion (%) of variation explained by covariateP valueCoefficient (95% CI)lVariable tested
Agomelatine v placebo (12 studies)
−11.200.6870.04947 (−0.2158 to 0.3148)Duration of treatment >6 weeks
0.350.4130.1043 (−0.1680 to 0.3766)Low risk of bias
20.380.1510.1652 (−0.0717 to 0.4021)Allocation concealment
Agomelatine v antidepressant (13 studies)
−15.980.748−0.0333 (−0.2557 to 0.1891)Duration of treatment >6 weeks
−33.930.6550.0006 (−0.0021 to 0.0033)Duration of current episode*
−17.460.8430.0191 (−0.1886 to 0.2268)Low risk of bias
38.470.0710.1645 (−0.0165 to 0.3456)Allocation concealment
*12 studies.
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Table 3| Real life examples of effect size*
ExampleDescriptionEffect size
Difference in height between girls aged 15 and 16Small0.2
Difference in height between girls aged 14 and 18Medium “visible to naked eye”0.5
Difference in height between girls aged 13 and 18Large “grossly perceptible”0.8
*Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Lawrence Erlbaum, 1988.
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Table 4| Other meta-analyses of agomelatine v placebo or other antidepressants
Antidepressant comparator studiesPlacebo studies
Reference OutcomeStudies/participants*OutcomeStudies/participants*
Agomelatine effect size (SMD) v
comparator†=0.11
5/1698Agomelatine effect size (SMD) v
placebo†=0.26
5/1963Singh, 2011
Mean difference in HAM-d score change=0.86
points†
6/2034NANilKasper, 2013
NANilAgomelatine effect size (SMD) v
placebo†=0.18
10/2896Koesters, 2013
Agomelatine effect size (SMD) v
comparator=0.00
13/4559Agomelatine effect size (SMD) v
placebo†=0.24
12/3951Current study
SMD=standardised mean difference; NA=not applicable.
*Number randomised.
†Agomelatine significantly better on measure described.
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Figures
Fig 1 Flow chart of identification and inclusion of studies on antidepressant efficacy of agomelatine
Fig 2 Risk of bias across studies on antidepressant efficacy of agomelatine
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Fig 3 Risk of bias within studies on antidepressant efficacy of agomelatine
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Fig 4 Standardised mean differences (SMD) for agomelatine v placebo in studies on antidepressant efficacy of agomelatine.
Weights are from random effects analysis
Fig 5 Risk ratios for response with agomelatine v placebo in studies on antidepressant efficacy of agomelatine. Weights
are from random effects analysis
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Fig 6 Risk ratios for remission with agomelatine v placebo in studies on antidepressant efficacy of agomelatine. Weights
are from random effects analysis
Fig 7 Standardised mean differences (SMD) for agomelatine v antidepressant in studies on antidepressant efficacy of
agomelatine. Weights are from random effects analysis
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Fig 8 Risk ratios for response with agomelatine v antidepressant in studies on antidepressant efficacy of agomelatine.
Weights are from random effects analysis
Fig 9 Risk ratios for remission with agomelatine v antidepressant in studies on antidepressant efficacy of agomelatine.
Weights are from random effects analysis
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Fig 10 Standardised mean differences for agomelatine v comparator by antidepressant in studies on antidepressant efficacy
of agomelatine. Weights are from random effects analysis
Fig 11 Risk ratios all cause discontinuation v placebo in studies on antidepressant efficacy of agomelatine. Weights are
from random effects analysis
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Fig 12 Risk ratios all cause discontinuation v antidepressant in studies on antidepressant efficacy of agomelatine. Weights
are from random effects analysis
Fig 13 Risk ratios for discontinuation because of adverse effects for agomelatine v placebo. Weights are from random
effects analysis
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Fig 14 Risk ratios for discontinuations because of adverse effects for agomelatine v another antidepressant. Weights are
from random effects analysis
Fig 15 Funnel plot of standardised mean differences (SMD) for agomelatine v placebo in studies on antidepressant efficacy
of agomelatine
Fig 16 Funnel plot standardised mean differences (SMD) for agomelatine v other antidepressant in studies on antidepressant
efficacy of agomelatine
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